Are Wall Street Analysts Predicting Intuitive Surgical Stock Will Climb or Sink?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 26 2024
0mins
Source: NASDAQ.COM
Company Overview and Performance: Intuitive Surgical, Inc. specializes in robotic-assisted surgical systems and has seen significant stock performance, gaining 68.7% over the past year compared to the S&P 500's 31.3%. The company reported strong Q3 earnings with a revenue increase of 17% year-over-year.
Analyst Ratings and Future Outlook: Analysts maintain a "Moderate Buy" consensus on ISRG stock, with expectations for a 34.6% EPS growth this fiscal year. Recent upgrades from analysts suggest potential price targets indicating further upside for investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISRG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 406.780
Low
575.00
Averages
637.32
High
740.00
Current: 406.780
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nvidia vs. Intuitive Surgical: AI Competition Insights
- AI Revolution Leader: Nvidia stands at the forefront of the global AI revolution with a current P/E ratio of 31x, which, while lower than Intuitive Surgical's 50x, still reflects strong investor interest in its AI chip market leadership.
- Surgical Robotics Demand: Intuitive Surgical has seen a robust demand for its surgical robots, with a 17% year-over-year increase in surgeries using da Vinci robots in Q1 2026, compared to a mere 12% increase in the number of da Vinci robots globally, indicating strong market demand.
- Diverse Revenue Streams: Only 25% of Intuitive Surgical's revenue comes from robot sales, with the remainder derived from services, instruments, and accessories that support da Vinci robots, creating annuity-like income streams that ensure stable cash flow for the company.
- Growth Opportunities: With the FDA's approval of the da Vinci Single Port surgical system for various procedures, Intuitive Surgical's market applications will expand, and the potential integration of AI technology could position it for long-term growth that may surpass Nvidia's market performance.
See More
Nvidia and Intuitive Surgical Market Competition
- Nvidia's Market Position: Nvidia is at the forefront of the global AI revolution with a current P/E ratio of 31x, attracting investor interest despite fierce competition and demonstrating strong business performance.
- Intuitive Surgical's Growth Potential: The number of surgeries performed with Intuitive Surgical's da Vinci robots rose 17% year-over-year in Q1 2026, indicating robust market demand, even though robot sales account for only 25% of the company's revenue.
- Diverse Revenue Streams: Intuitive Surgical's income is not solely from robot sales; it also includes services and accessories, creating annuity-like revenue streams that ensure long-term financial stability for the company.
- Technological Innovation and Market Opportunities: With the FDA's clearance of the da Vinci Single Port surgical system for various procedures, Intuitive Surgical's market applications will expand, and the potential integration of AI technology offers new growth avenues for the future.
See More
Investment Opportunities in Healthcare Sector
- Vertex Pharmaceuticals' Market Leadership: Vertex Pharmaceuticals leads the global cystic fibrosis treatment market, with its flagship product Trikafta and the newly launched Alyftrek contributing to a 25% growth in the recent quarter, indicating strong market demand and future growth potential.
- Intuitive Surgical's Competitive Advantage: As the global leader in robotic surgery, Intuitive Surgical ensures long-term revenue growth through its Da Vinci robot and recurring service contract revenues, while the high investment cost of its robotic systems encourages hospitals to stick with their purchases for extended periods.
- Strong Financial Performance: Johnson & Johnson achieved nearly 10% revenue growth in Q1, with expectations to reach $100 billion in revenue for 2023, supported by 28 projects generating over $1 billion annually, providing a robust foundation for future growth.
- Sustained Dividend Growth: Johnson & Johnson, known as a 'Dividend King', recently raised its dividend for the 64th consecutive year, demonstrating its commitment to shareholder returns and reflecting the company's stable earnings growth and financial health.
See More
Investment Opportunities in Healthcare Sector
- Vertex Pharmaceuticals' Market Leadership: Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment, with its top drug Trikafta and the newly launched Alyftrek contributing to a 25% growth in the recent quarter, indicating strong market demand and future expansion potential.
- Intuitive Surgical's Competitive Advantage: As the global leader in robotic surgery, Intuitive Surgical has established a strong moat with its Da Vinci robot, ensuring hospitals' long-term investment in its equipment, which guarantees a continuous revenue stream, especially as service contracts and accessory sales constitute a larger share of revenue.
- Robust Financial Growth: Johnson & Johnson achieved nearly 10% revenue growth in Q1 2023, with expectations to reach $100 billion in revenue this year, and its 28 programs generating over $1 billion annually lay a solid foundation for future double-digit growth.
- Commitment to Dividend Growth: As a Dividend King, Johnson & Johnson has raised its dividend for the 64th consecutive year, demonstrating its focus on shareholder returns and reflecting its stable earnings growth capability, making it an ideal long-term investment.
See More
Intuitive Surgical Appoints New Chief Commercial Officer
- Executive Appointment: Intuitive Surgical announced the promotion of Taylor Patton to Chief Commercial and Marketing Officer effective July 1, leveraging nearly two decades of experience to oversee global commercial operations and marketing strategies, which is expected to drive business expansion during a period of global growth.
- Leadership Transition: Current Chief Commercial and Marketing Officer Henry Charlton will transition to Senior Vice President of Global Business Operations, focusing on generating global value for patients and healthcare systems while ensuring a seamless leadership transition, thereby enhancing operational efficiency.
- Strategic Objectives: CEO Dave Rosa emphasized that Patton's extensive experience across the da Vinci, Ion, and Digital platforms positions him well to scale the company's commercial operations during global growth, aligning with the company's strategic goal of expanding access to minimally invasive care.
- Market Potential: While there is optimism regarding ISRG's investment potential, analysts suggest that certain AI stocks offer greater upside potential and lower downside risk, reflecting a diverse market focus and investment strategies across different technology sectors.
See More
Citadel Advisors Increases Stake in Intuitive Surgical Amid Market Challenges
- AI Stock Reduction: Citadel Advisors sold 2.9 million shares of Nvidia and 6 million shares of Amazon in Q1, although both remain among its largest holdings, indicating a strategic shift to reallocate capital into more attractive investment opportunities.
- Healthcare Stake Increase: The firm increased its stake in Intuitive Surgical by 30.3% during the first quarter, reflecting confidence in the company's long-term prospects despite facing multiple challenges from competition, lower-margin products, and tariffs.
- Intensifying Market Competition: Intuitive Surgical is encountering increased competition in the robotic-assisted surgery market from Medtronic and Johnson & Johnson; however, the company maintains a significant lead due to its 26 years of market experience and extensive installed base.
- Profitability Outlook: Despite Intuitive Surgical's high valuation with a forward P/E ratio of 39.7, its revenue and earnings growth outpace peers, and its strong competitive edge in the medical device sector justifies this premium.
See More
Nvidia vs. Intuitive Surgical: AI Competition Insights
- AI Revolution Leader: Nvidia stands at the forefront of the global AI revolution with a current P/E ratio of 31x, which, while lower than Intuitive Surgical's 50x, still reflects strong investor interest in its AI chip market leadership.
- Surgical Robotics Demand: Intuitive Surgical has seen a robust demand for its surgical robots, with a 17% year-over-year increase in surgeries using da Vinci robots in Q1 2026, compared to a mere 12% increase in the number of da Vinci robots globally, indicating strong market demand.
- Diverse Revenue Streams: Only 25% of Intuitive Surgical's revenue comes from robot sales, with the remainder derived from services, instruments, and accessories that support da Vinci robots, creating annuity-like income streams that ensure stable cash flow for the company.
- Growth Opportunities: With the FDA's approval of the da Vinci Single Port surgical system for various procedures, Intuitive Surgical's market applications will expand, and the potential integration of AI technology could position it for long-term growth that may surpass Nvidia's market performance.
See More
Nvidia and Intuitive Surgical Market Competition
- Nvidia's Market Position: Nvidia is at the forefront of the global AI revolution with a current P/E ratio of 31x, attracting investor interest despite fierce competition and demonstrating strong business performance.
- Intuitive Surgical's Growth Potential: The number of surgeries performed with Intuitive Surgical's da Vinci robots rose 17% year-over-year in Q1 2026, indicating robust market demand, even though robot sales account for only 25% of the company's revenue.
- Diverse Revenue Streams: Intuitive Surgical's income is not solely from robot sales; it also includes services and accessories, creating annuity-like revenue streams that ensure long-term financial stability for the company.
- Technological Innovation and Market Opportunities: With the FDA's clearance of the da Vinci Single Port surgical system for various procedures, Intuitive Surgical's market applications will expand, and the potential integration of AI technology offers new growth avenues for the future.
See More
Investment Opportunities in Healthcare Sector
- Vertex Pharmaceuticals' Market Leadership: Vertex Pharmaceuticals leads the global cystic fibrosis treatment market, with its flagship product Trikafta and the newly launched Alyftrek contributing to a 25% growth in the recent quarter, indicating strong market demand and future growth potential.
- Intuitive Surgical's Competitive Advantage: As the global leader in robotic surgery, Intuitive Surgical ensures long-term revenue growth through its Da Vinci robot and recurring service contract revenues, while the high investment cost of its robotic systems encourages hospitals to stick with their purchases for extended periods.
- Strong Financial Performance: Johnson & Johnson achieved nearly 10% revenue growth in Q1, with expectations to reach $100 billion in revenue for 2023, supported by 28 projects generating over $1 billion annually, providing a robust foundation for future growth.
- Sustained Dividend Growth: Johnson & Johnson, known as a 'Dividend King', recently raised its dividend for the 64th consecutive year, demonstrating its commitment to shareholder returns and reflecting the company's stable earnings growth and financial health.
See More
Investment Opportunities in Healthcare Sector
- Vertex Pharmaceuticals' Market Leadership: Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment, with its top drug Trikafta and the newly launched Alyftrek contributing to a 25% growth in the recent quarter, indicating strong market demand and future expansion potential.
- Intuitive Surgical's Competitive Advantage: As the global leader in robotic surgery, Intuitive Surgical has established a strong moat with its Da Vinci robot, ensuring hospitals' long-term investment in its equipment, which guarantees a continuous revenue stream, especially as service contracts and accessory sales constitute a larger share of revenue.
- Robust Financial Growth: Johnson & Johnson achieved nearly 10% revenue growth in Q1 2023, with expectations to reach $100 billion in revenue this year, and its 28 programs generating over $1 billion annually lay a solid foundation for future double-digit growth.
- Commitment to Dividend Growth: As a Dividend King, Johnson & Johnson has raised its dividend for the 64th consecutive year, demonstrating its focus on shareholder returns and reflecting its stable earnings growth capability, making it an ideal long-term investment.
See More
Intuitive Surgical Appoints New Chief Commercial Officer
- Executive Appointment: Intuitive Surgical announced the promotion of Taylor Patton to Chief Commercial and Marketing Officer effective July 1, leveraging nearly two decades of experience to oversee global commercial operations and marketing strategies, which is expected to drive business expansion during a period of global growth.
- Leadership Transition: Current Chief Commercial and Marketing Officer Henry Charlton will transition to Senior Vice President of Global Business Operations, focusing on generating global value for patients and healthcare systems while ensuring a seamless leadership transition, thereby enhancing operational efficiency.
- Strategic Objectives: CEO Dave Rosa emphasized that Patton's extensive experience across the da Vinci, Ion, and Digital platforms positions him well to scale the company's commercial operations during global growth, aligning with the company's strategic goal of expanding access to minimally invasive care.
- Market Potential: While there is optimism regarding ISRG's investment potential, analysts suggest that certain AI stocks offer greater upside potential and lower downside risk, reflecting a diverse market focus and investment strategies across different technology sectors.
See More
Citadel Advisors Increases Stake in Intuitive Surgical Amid Market Challenges
- AI Stock Reduction: Citadel Advisors sold 2.9 million shares of Nvidia and 6 million shares of Amazon in Q1, although both remain among its largest holdings, indicating a strategic shift to reallocate capital into more attractive investment opportunities.
- Healthcare Stake Increase: The firm increased its stake in Intuitive Surgical by 30.3% during the first quarter, reflecting confidence in the company's long-term prospects despite facing multiple challenges from competition, lower-margin products, and tariffs.
- Intensifying Market Competition: Intuitive Surgical is encountering increased competition in the robotic-assisted surgery market from Medtronic and Johnson & Johnson; however, the company maintains a significant lead due to its 26 years of market experience and extensive installed base.
- Profitability Outlook: Despite Intuitive Surgical's high valuation with a forward P/E ratio of 39.7, its revenue and earnings growth outpace peers, and its strong competitive edge in the medical device sector justifies this premium.
See More
